1. Home
  2. QUBT vs SNDX Comparison

QUBT vs SNDX Comparison

Compare QUBT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum Computing Inc.

QUBT

Quantum Computing Inc.

HOLD

Current Price

$11.29

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$19.78

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QUBT
SNDX
Founded
2001
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
QUBT
SNDX
Price
$11.29
$19.78
Analyst Decision
Buy
Strong Buy
Analyst Count
6
13
Target Price
$17.50
$38.69
AVG Volume (30 Days)
18.6M
1.7M
Earning Date
05-13-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
84.93
11.56
EPS
N/A
N/A
Revenue
$682,000.00
$172,352,000.00
Revenue This Year
$3,210.56
$107.19
Revenue Next Year
$51.26
$41.88
P/E Ratio
N/A
N/A
Revenue Growth
82.84
627.84
52 Week Low
$6.18
$8.59
52 Week High
$25.84
$25.59

Technical Indicators

Market Signals
Indicator
QUBT
SNDX
Relative Strength Index (RSI) 59.49 41.02
Support Level $10.12 $19.35
Resistance Level $13.14 $22.40
Average True Range (ATR) 1.04 1.00
MACD -0.05 -0.01
Stochastic Oscillator 40.40 21.14

Price Performance

Historical Comparison
QUBT
SNDX

About QUBT Quantum Computing Inc.

Quantum Computing Inc is an integrated photonics and non-linear quantum optics company to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging, and cybersecurity applications based on patented and proprietary photonics technology. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offers capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: